CNS Drugs

, Volume 18, Issue 15, pp 1149–1163

The PROMISE Study: PROphylaxis of Migraine with SEglor® (Dihydroergotamine Mesilate) in French Primary Care

  • André Pradalier
  • Michel Lantéri-Minet
  • Gilles Géraud
  • Hervé Attain
  • Christian Lucas
  • Antonio Delgado
Original Research Article

DOI: 10.2165/00023210-200418150-00009

Cite this article as:
Pradalier, A., Lantéri-Minet, M., Géraud, G. et al. CNS Drugs (2004) 18: 1149. doi:10.2165/00023210-200418150-00009


Introduction: Seglor® capsules, a unique modified-release formulation of dihydroergotamine mesilate, have long been in clinical use in France for migraine prophylaxis. The aim of the PROMISE (PROphylaxis of Migraine with SEglor®) study was to establish the efficacy and tolerability of Seglor® in the prevention of migraine in a general practice setting.

Methods: The PROMISE study was a double blind, placebo-controlled, parallel-group study carried out in primary care practice. It included 363 migraine patients treated with Seglor® or placebo for 5 months after a 1-month placebo run-in phase.

Results: Migraine attack frequency (primary efficacy criterion) decreased markedly in the two treatment groups so that the difference in favour of Seglor® did not reach statistical significance. However, most secondary outcome measures (duration of single attack, total duration of attacks over 1 month, consumption of mild opiate analgesics, subjective improvement) improved to a significantly greater degree in patients receiving Seglor® than in those receiving placebo. In the 84.5% of patients who had impaired quality of life at entry, the percentage of reduction in attack frequency and most other efficacy measures showed significant improvement with Seglor®. The safety profile for Seglor® was comparable to that of placebo.

Conclusion: These results support the effectiveness of Seglor® in patients with migraine-related quality-of-life impairment. The findings of the PROMISE study also suggest that patients’ quality of life should be assessed systematically before initiating a preventive treatment for migraine.

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • André Pradalier
    • 1
  • Michel Lantéri-Minet
    • 2
  • Gilles Géraud
    • 3
  • Hervé Attain
    • 4
  • Christian Lucas
    • 5
  • Antonio Delgado
    • 6
  1. 1.Service de Médecine Interne 4, Centre Migraines et CéphaléesHôpital Louis MourierColombesFrance
  2. 2.Department of Evaluation and Treatment of PainPasteur HospitalNiceFrance
  3. 3.Rangueil University Teaching HospitalToulouseFrance
  4. 4.Pontchaillou HospitalRennesFrance
  5. 5.Neurological ClinicSalengro HospitalLilleFrance
  6. 6.Schwarz Pharma FranceBoulogne-BillancourtFrance

Personalised recommendations